DOCSLIB.ORG

Preventive Effects of Multi-Lamellar Emulsion on Low Potency Topical Steroid Induced Local Adverse Effect

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preventive Effects of Multi-Lamellar Emulsion on Low Potency Topical Steroid Induced Local Adverse Effect Ann Dermatol Vol. 25, No. 1, 2013 http://dx.doi.org/10.5021/ad.2013.25.1.5 ORIGINAL ARTICLE Preventive Effects of Multi-Lamellar Emulsion on Low Potency Topical Steroid Induced Local Adverse Effect Geun Dong Sul, Hyun Jung Park1, Jong Hwan Bae1, Keum Duck Hong1, Byeong Deog Park1, Jaesun Chun, Se Kyoo Jeong1, Seung Hun Lee2, Sung Ku Ahn3, Hyun Jung Kim4 Department of Biology Education, Korea National University of Education, Cheongwon, 1Research Division, NeoPharm Co., Ltd., Daejeon, 2Department of Dermatology, Yonsei University College of Medicine, Seoul, 3Department of Dermatology, Yonsei University, Wonju College of Medicine, Wonju, 4Department of Dermatology, Atopy and Asthma Center, Seoul Medical Center, Seoul, Korea Background: Topical steroid treatment induces diverse local adverse effects, including permeability barrier function Wand systemic adverse effects. Several approaches have impairment, were partially prevented by MLE formulation. been tried to reduce the steroid-induced adverse effects. Conclusion: Topical desonide formulation using MLE as a Simultaneous application of physiological lipid mixture is vehicle showed a better drug delivery with increased also suggested. Objective: Novel vehicles for topical epidermal retention. MLE also partially prevented the glucocorticoids formulation were evaluated for the efficacy steroid-induced side effects, such as skin barrier impairment. of reducing side-effects and the drug delivery properties of (Ann Dermatol 25(1) 5∼11, 2013) desonide, a low potency topical steroid. Methods: Trans- cutaneous permeation and skin residual amount of desonide -Keywords- were measured using Franz diffusion cells. The in vivo Epidermal permeability barrier function, Multilamellar anti-inflammatory activity was evaluated using murine emulsion, Skin permeation, Topical glucocorticoids model. Results: Topical steroids formulation containing de- sonide, in either cream or lotion form, were prepared using multi-lamellar emulsion (MLE), and conventional desonide INTRODUCTION formulations were employed for comparison. MLE for- mulations did not affect the anti-inflammatory activity of the Topical glucocorticoid therapy is one of the most com- desonide in phobol ester-induced skin inflammation model, monly used immunosuppressive or anti-inflammatory drugs. compared with conventional formulations. While the pene- Even with the invaluable therapeutic efficacies, however, trated amounts of desonide were similar for all the tested inevitable local side effects including skin atrophy, striae, formulations at 24 hours after application, the increased lag telangiectasis, prupura, acneform eruption, perioral der- time was observed for the MLE formulations. Interestingly, matitis, and steroid-induced rosacea impede the long-term residual amount of desonide in epidermis was significantly use of steroids for chronic skin diseases such as atopic higher in lotion type MLE formulation. Steroid-induced dermatitis. Recently, it was also reported that both the long-term and short-term application of topical steroids Received August 12, 2010, Revised October 26, 2011, Accepted for can compromise the skin barrier function, mainly by inhi- publication October 28, 2011 biting the epidermal lipid synthesis1,2. Corresponding author: Hyun Jung Kim, Department of Dermatology, Various strategies to minimize the steroid-induced side Atopy and Asthma Center, Seoul Medical Center, 156 Sinnae-ro, Jungnang-gu, Seoul 131-865, Korea. Tel: 82-2-2276-7891, Fax: 82-2- effects have been suggested, including modification of 3-5 6 2276-7438, E-mail: [email protected] application schedules , designing new steroid molecules , This is an Open Access article distributed under the terms of the and adjunctive use of other drugs with anti-atrophogenic Creative Commons Attribution Non-Commercial License (http:// activity7. Use of new vehicles for topical steroids is also creativecommons.org/licenses/by-nc/3.0) which permits unrestricted suggested as an effective way of reducing the side-effects non-commercial use, distribution, and reproduction in any medium, of steroids, as well as improving the transcutaneous de- provided the original work is properly cited. Vol. 25, No. 1, 2013 5 GD Sul, et al livery and epidermal release profile. It has been reported same 0.05% desonide were used for comparison. that a hydrogel formulation containing desonide, a low Preparation of test formulations potency corticosteroid, had an improved risk-benefit ratio in atopic dermatitis patients8,9. Recently, we have shown In order to prepare MLE vehicle, the lipid components that a multi-lamellar emulsion (MLE), as a vehicle for clo- (pseudoceramide, stearic acid, and cholesterol), oils, co- betasol 17-propionate, is effective for preventing the ste- mmon base (cetanol, 2-octyldodecanol, squalane, and roid-induced skin atrophy and epidermal permeability fatty acid triglyceride) and emulsifiers (glyceryl mono- barrier function impairment10. stearate, POE(15) glyceryl monostearate) were mixed and In the present study, the effects of MLE as a vehicle for melted at 85 to 90oC. The desonide was dissolved in 1, topical steroids is further investigated. Desonide, a low 3-butylene glycol and then slowly added with vigorous potency glucocorticoid, is formulated into MLE, and the agitation by homomixer (T.K. Homomixer Mark II f-model, anti-inflammatory activity and transcutaneous delivery Tokyo Co., Ltd., Tokyo, Japan) at 70oC. After emulsifying, were measured. Steroid-induced side effects on skin atro- the mixture was cooled down to the room temperature. phy and skin barrier function were also evaluated in All formulations were prepared containing 0.05% deso- animal model. nide of the final content (Table 1). Detailed preparation scheme was previously reported12. MATERIALS AND METHODS In vivo efficacy measurement Materials Female hairless mouse (8 weeks old) and male ICR mice Stearic acid, cholesterol, and fatty acid triglyceride were (4 weeks old) were purchased from Orient Bio Co. purchased from Junsei Chemical Co. (Tokyo, Japan); and (Seongnam, Korea) and kept under controlled humidity (50∼ glyceryl monostearate and POE(15) glyceryl monostearate 60%) and temperature (23∼25oC) with a 12 hr/12 hr were from Nihon Emulsion Co (Tokyo, Japan). Cetanol (light/dark) cycle. All the animal experiments described (Kao Co., Tokyo, Japan) and squalane (Kishimoto Co., were approved by the Institutional Review Board of Hyogo, Japan) were used for the preparation of emulsions. Yonsei University College of Medicine. Synthesis of pseudoceramide (myristyl/palmityl oxostearamide/ In order to observe the steroid-induced skin atrophy, arachamide MEA: C34H67NO3/C36H71NO3/C38H75NO3=11 ： tested formulations were applied to the entire dorsal skin 42：47%) and its chemical characteristics were described of hairless mouse twice a day for 3 days. Skin double-fold in a previous report11. Desonide was obtained from Hubei thickness was measured using digital calipers (Mitutoyo Gedian Humanwell Pharmaceutical Co., Ltd. (Hubei, Co., Ltd., Kawasaki, Japan). Epidermal permeability barrier China). Commercial cream and lotion products containing function and skin hydration were evaluated by measuring Table 1. The main components of tested formulations Conventional lotion Conventional cream MLE/desonide cream MLE/desonide lotion Desonide (0.05%) Sorbic acid Methyl hydroxybenzoate Pseudo-stratum corneum Pseudo-stratum corneum lipid (1.6%) lipid (2.3%) Potassium sorbate Propyl hydroxybenzoate Methyl hydroxybenzoate Methyl hydroxybenzoate Propylene glycol Propylene glycol Propyl hydroxybenzoate Propyl hydroxybenzoate Citric acid Citric acid Butylenes glycol Butylenes glycol Sodium hydroxide Sodium hydroxide Arginine Arginine Polysorbate 60 Sorbitan monostearate PEG-15 glyceryl stearate PEG-15 glyceryl stearate Emulsifying wax Self-emulsifying glyceryl Glyceryl monosterate Glyceryl monosterate monosterate Isopropyl palmitate Sodium lauryl sulphate Cetanol Cetanol Stearic acid Light liquid paraffin Squalane Squalane Synthetic beeswax Cetyl alcohol Liquid paraffin Liquid paraffin Propyl gallate Stearyl alcohol BHT BHT Purified water Tetrasodium EDTA Purified water Purified water Purified water MLE: multi-lamellar emulsion, EDTA: ethylenediaminetetraacetic acid, BHT: butylated hydroxytoluene. 6 Ann Dermatol The Preventive Effect of MLE Cream to Steroid Side Effect trans-epidermal water loss (TEWL) and skin capacitance, hydrated in 0.05% sodium chloride solution for 30 respectively. Measurement of TEWL and skin capacitance minutes and cut into appropriate pieces. The skin sections was performed using Tewameter TM 300 (Courage & were mounted on surface areas of 0.785 cm2 occluded Khazaka, Cologne, Germany) and Corneometer CM 820 Franz diffusion cells and the acceptor compartment was (Courage & Khazaka), respectively. filled with phosphate buffer pH 7.4. The epidermal side of Anti-inflammatory activity of desonide formulation was the skin was exposed to ambient environment and evaluated using mice ear model, and the skin inflamma- allowed to equilibrate for 1 hour before experiment. After tion was induced by repeated treatment of 12-O-tetrade- equilibration, 40 mg of each formulation was placed on canoylphorbol-13-acetate (TPA) for 7 days. TPA (1 μg/ skin surface using a spatula and receptor solution was 20 μl acetone) was applied to the mouse ear (day 0). The maintained at 37±0.5oC and stirred continuously at 600 tested formulations were then topically applied to the rpm. The receptor solution (4 ml) was taken
Load more

Recommended publications
  • DESONATE® (Desonide) Gel 0.05% for Topical Use Only • Systemic Absorption May Require Evaluation for HPA Axis Suppression Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use • Topical corticosteroids can produce reversible hypothalamic pituitary DESONATE Gel safely and effectively. See full prescribing information adrenal (HPA) axis suppression, Cushing's syndrome and unmask latent for DESONATE Gel. diabetes. (5.1) DESONATE® (desonide) Gel 0.05% for topical use only • Systemic absorption may require evaluation for HPA axis suppression Initial U.S. Approval: 1972 (5.1). • Modify use should HPA axis suppression develop (5.1) ---------------------------- INDICATIONS AND USAGE--------------------------- • Potent corticosteroids, use on large areas, prolonged use or occlusive use may increase systemic absorption (5.1) DESONATE is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. (1) • Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be ---------------------- DOSAGE AND ADMINISTRATION----------------------- more likely with occlusive use or more potent corticosteroids. (5.2, 5.4, 6) • Apply as a thin layer to the affected areas two times daily and rub in • Children may be more susceptible to systemic toxicity when treated with gently. (2) topical corticosteroids. (5.1, 8.4) • Therapy should be discontinued when control is achieved. (2) • If no improvement is seen within 4 weeks, reassessment of diagnosis ------------------------------ ADVERSE REACTIONS------------------------------- may be necessary. (2) The most common adverse reactions (incidence ≥ 1%) are headache and • Should not be used with occlusive dressings. (2) application site burning. (6) • Treatment beyond 4 consecutive weeks is not recommended. (2) To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma • For topical use only.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Medical Review~ Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21-978 MEDICAL REVIEW~ CLINICAL REVIEW Application Type NDA Submission Number 21-978 Submission Code 000 Letter Date November 18, 2005 Stamp Date November 28, 2005 PDUFA Goal Date September 21,2006 Reviewer Name Denise Cook, M.D. Review Completion Date 8/28/06 Established Name Desonide (Proposed) Trade Name .. Therapeutic Class Topical corticosteroid Applicant Connectics Priority Designatiop S Formulation Foam, 0.05% Dosing Regimen bid Indication F or the treatment of mild to moderate atopic dermatitis . Intended Population Age 3 months and above Clinical Review Denise Cook, M.D. NDA 21-978/ N-OOO _ loam, 0.05%/desonide foam, 0.05% Table of Contents 1 EXECUTIVE SUMMARy................................................................................................................................5 1.1 RECOMMENDATION ON REGULATORY ACTION ...........................................................................................5 1 .2 RECOMMENDATION ON POSTMARKETING ACTIONS. .............. ...... .... .... ........... ........ ..... ... ..... ...... ......... ........5 1.2. I Risk Management Activity................ ......... ..... ............... ..... ................... ........ ........ .... ....... ... ......... ........5 1.2.2 Required Phase 4 Commitments............................................................................................................5 1.2.3 Other Phase 4 Requests..........................................................................................................................5
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Pre - PA Allowance Age 18 Years of Age Or Older Quantity 60 Grams Every 90 Days ______
    DOXEPIN CREAM 5% (Prudoxin, Zonalon) Pre - PA Allowance Age 18 years of age or older Quantity 60 grams every 90 days _______________________________________________________________ Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: Moderate pruritus, due to atopic dermatitis (eczema) or lichen simplex chronicus AND the following: 1. Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: a. Topical antihistamine (see Appendix I) b. High potency topical corticosteroid (see Appendix II) 2. Physician agrees to taper patient’s dose to the FDA recommended dose, and after tapered will only use for short-term pruritus relief (up to 8 days) a. Patients using over 60 grams of topical doxepin in 90 days be required to taper to 60 grams topical doxepin within 90 days Prior - Approval Limits Quantity 180 grams for 90 days Duration 3 months ___________________________________________________________________ Prior – Approval Renewal Requirements None (see appendix below) Doxepin 5% cream FEP Clinical Rationale DOXEPIN CREAM 5% (Prudoxin, Zonalon) APPENDIX I Drug Dosage Form Diphenhydramine Cream Phenyltoloxamine Lotion/ Cream Tripelennamine Cream Phendiamine Cream APPENDIX II Relative Potency of Selected Topical Corticosteroid Drug ProductsDosage Form Strength I. Very high potency Augmented betamethasone Ointment, Gel 0.05% dipropionate Clobetasol propionate Cream, Ointment 0.05% Diflorasone diacetate Ointment 0.05% Halobetasol propionate Cream, Ointment 0.05% II. High potency Amcinonide Cream, Lotion, 0.1% Augmented betamethasone Cream,Ointment Lotion 0.05% dipropionate Betamethasone Cream, Ointment 0.05% Betamethasonedipropionate valerate Ointment 0.1% Desoximetasone Cream, Ointment 0.25% Gel 0.05% Diflorasone diacetate Cream, Ointment 0.05% (emollient base) Fluocinonide Cream, Ointment, Gel 0.05% Halcinonide Cream, Ointment 0.1% Triamcinolone acetonide Cream, Ointment 0.5% III.
    [Show full text]
  • Attorney General Frosh Announces Filing of 3Rd Multistate Lawsuit
    Brian E. Frosh Media Contacts: Attorney General [email protected] 410-576-7009 Attorney General Frosh Announces Filing of 3rd Multistate Lawsuit Against Sandoz, Inc., 26 Other Generic Manufacturers, 10 Individuals in Generic Drug Price-Fixing Conspiracy BALTIMORE, MD (June 10, 2020) - Maryland Attorney General Brian E. Frosh today announced a multistate lawsuit against Sandoz, Inc. and 26 of the nation’s largest generic drug manufacturers, alleging a broad conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for generic drugs sold across the United States. This new complaint, filed in the U.S. District Court for the District of Connecticut, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States. The complaint names 26 corporate defendants and 10 individual defendants. The lawsuit seeks damages, civil penalties, and actions by the court to restore competition to the generic drug market. The topical drugs at the center of the complaint include creams, gels, lotions, ointments, shampoos, and solutions used to treat a variety of skin conditions, pain, and allergies. The complaint stems from an ongoing investigation built on evidence from several cooperating witnesses at the core of the conspiracy, a massive document database of over 20 million documents, and a phone records database containing millions of call detail records and contact information for over 600 sales and pricing individuals in the generics industry. Among the records obtained by the States is a two-volume notebook containing the contemporaneous notes of one of the States’ cooperators that memorialized his discussions during phone calls with competitors and internal company meetings over a period of several years.
    [Show full text]
  • Desonide Cream, 0.05%Desonide Ointment, 0.05%
    DESONIDE- desonide cream DESONIDE- desonide ointment Taro Pharmaceuticals U.S.A., Inc. ---------- Desonide Cream, 0.05% Desonide Ointment, 0.05% For Dermatologic Use Only Not For Ophthalmic Use Rx Only DESCRIPTION Desonide Cream, 0.05% and Desonide Ointment, 0.05% contain desonide (Pregna-1,4-diene-3,20- dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α-)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in Desonide Cream, 0.05% and Desonide Ointment, 0.05%, is C24H32O6. It has the following structural formula: The molecular weight of desonide is 416.51. It is a white to off-white odorless powder which is soluble in methanol and practically insoluble in water. Each gram of Desonide Cream, 0.05% contains 0.5 milligram of desonide in a compatible vehicle buffered to the pH range of normal skin. It contains aluminum acetate basic, cetearyl alcohol/sodium lauryl sulfate/sodium cetearyl sulfate, glycerin, mineral oil, purified water, white petrolatum and white wax. It is preserved with methylparaben. Each gram of Desonide Ointment, 0.05% contains 0.5 milligram of desonide in an ointment base consisting of mineral oil and white petrolatum. It is a smooth, uniform petrolatum-type ointment. CLINICAL PHARMACOLOGY Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.
    [Show full text]
  • Chronic Vulvar Irritation, Itching, and Pain. What Is the Diagnosis?
    SECOND OF 2 PARTS ON OFFICE MANAGEMENT OF BENIGN VULVAR CONDITIONS Chronic vulvar irritation, itching, and pain. What is the diagnosis? Five cases of dermatoses, vaginal abnormalities, and pain syndromes that may masquerade as infection Libby Edwards, MD, and Beth E. Goldbaum, MD hronic irritation, itching, and pain CASE 1 Introital burning and a fear are only rarely due to infection. of breast cancer C These symptoms are more likely to A 56-year-old woman visits your office for be caused by dermatoses, vaginal abnormali- management of recent-onset introital burn- ties, and pain syndromes that may be difficult ing during sexual activity. She reports that to diagnose. Careful evaluation should in- her commercial lubricant causes irritation. clude a wet mount and culture to eliminate Topical and oral antifungal therapies have not infection as a cause so that the correct diag- been beneficial. She has a strong family his- IN THIS nosis can be ascertained and treated. tory of breast cancer. ARTICLE In Part 2 of this two-part series, we focus On examination, she exhibits small, When a woman on five cases of vulvar dermatologic disrup- smooth labia minora and experiences pain is reluctant to use tions: when a cotton swab is pressed against the local estrogen • atrophic vagina vestibule. The vagina is also smooth, with page 32 • irritant and allergic contact dermatitis scant secretions. Microscopically, these • complex vulvar aphthosis secretions are almost acellular, with no • desquamative inflammatory vaginitis increase in white blood cells and no clue A teenager • inverse psoriasis. cells, yeast forms, or lactobacilli. The pH is with vulvar pain greater than 6.5, and most epithelial cells are and sores parabasal (FIGURE 1, page 32).
    [Show full text]
  • Desonide Cream and Ointment)
    PRODUCT MONOGRAPH Prpdp-DESONIDE (Desonide Cream and Ointment) 0.05% (w/w) Glucocorticoid PENDOPHARM, Division of Pharmascience Inc. Date of Revision: 6111 Royalmount Ave, Suite #100 March 26, 2021 Montreal, Quebec H4P 2T4 Control number: 245004 1 Prpdp-DESONIDE (Desonide Cream and Ointment) 0.05% (w/w) THERAPEUTIC CLASSIFICATION Glucocorticoid ACTIONS AND CLINICAL PHARMACOLOGY pdp-DESONIDE (desonide) 0.05% is an anti-inflammatory and antipruritic corticosteroid designed for topical use in inflammatory dermatoses. Human dose titration studies were carried out using two different methods, both in a double-blind randomized fashion with fluocinolone acetonide 0.025% as the reference steroid. In the first method, patients with symmetrical bilateral skin lesions were selected. In the second method, ambulatory or hospitalized patients afflicted with stabilized psoriasis were employed. In the former investigation desonide 0.025% cream was found equipotent with fluocinolone acetonide 0.025%. However, using the sign test at a significant level of α=0.05, the same concentration of desonide was shown to be superior (p<0.03) to fluocinolone acetonide 0.025% on first week objective evaluation. The second investigation yielded similar results. Human systemic effects studies were carried out with desonide cream 0.02% in parallel with fluocinolone acetonide cream 0.01% on patients with 10%, 30%, 60%, and 90% of the body surface treated and occluded for one week in a double-blind design. All of the patients had dermatoses responsive to corticosteroid preparations, primarily psoriasis or exfoliative dermatitis, but a rare patient was included who had an eczematous dermatitis. The patients were divided into groups of six according to body surface involvement with random assignment to the steroids under investigation.
    [Show full text]
  • Center for Drug Evaluation and Research
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21..844 ADMINISTRATIVE and CORRSPONDENCE DOCUMENTS NDA # 021844 Administrative Information and Product Labeling tUS J Dow Pharmaceutical Sciences, Inc Page 1 1.3.5.2 Patent Certifcation Desonide Gel, 0.05% Paragraph II Certification The Sponsor, Skin Medica, seeks marketing approval of DesonateQY Hydrogel, 0.05% in the treatment of atopic dermatitis via a 505(b )(2) application. Desonate(ß Hydrogel, 0.05% is protected under US Patent No. 6,387,383 B-1; issued May 14,2002. Since the patent was filed on August 3,2000 and does not claim priority from any earlier filed application, the expiration date of the patent wil be August 3,2020. To the best of Skin Medica's knowledge, any other patents relating to desonide gel have expired and DesonateQY Hydrogel, 0.05% does not infringe on any existing patents. There is not a patent in effect for Des OwenQY Lotion. APPEARS THIS WAY ON OlUGINAl . PATENT CERTIFICATION 12/0612005 NDA # 021844 Administrative Information and Product Labeling (US J Dow Pharmaceutical Sciences, Inc Page 1 . Department of Health and Human Services Form Approved: OMB No. 0910-0513 Food and Drug Administration .Expiration Date: 07/31/06 See OMS Statement on Page 3. PATENT INFORMATION SUBMITTED WITH THE NDANUMBER FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT 021844 For Each Patent That Claims a Drug Substance NAME OF APPLICANT / NDA HOLDER (Active Ingredient), Drug Product (Formulation and Skin Medica Compositon) and/or Method of Use The fol/owing is provided in accordance with Section 505(b) and (c) of the Federal Food, Drug, and Cosmetic Act TRADE NAME (OR PROPOSED TRADE NAME) DesonatelI Hydrogel .
    [Show full text]
  • Formulary and Program Updates Effective 8/1/18
    Formulary and Program Updates Effective 8/1/18 Pharmacy & Therapeutics Committee Meeting May 22, 2018 6:30 – 8:00 PM Role Call VOTING MEMBERS NON-VOTING MEMBERS • David Konanc, MD • Carl Antolick III, PharmD • Matthew K. Flynn, MD • Tracy Linton, MPH • Jennifer Burch, PharmD • Dee Jones • Peter Robie, MD • Lucy Barreto, DDS, MHA • Tony Gurley, RPh, JD • Renee Jarnigan, RPh • Michael Spiritos, MD • Stephanie Morrison, PharmD • John B. Anderson, MD, MPH • John Engemann, MD • Joseph Shanahan, MD 2 Ethics Awareness & Conflict of Interest Reminder In accordance with the NC State Health Plan for Teachers and State Employees’ ethics policy, it is the duty of every member of the Pharmacy & Therapeutics Committee, whether serving in a vote casting or advisory capacity, to avoid both conflicts of interest and appearances of conflict. Does any Committee member have any known conflict of interest or the appearance of any conflict with respect to any manufacturers of any medication to be discussed at today’s meeting? Or, if during the course of the evaluation process if you identify a conflict of interest or the appearance of a conflict. If so, please identify the conflict or appearance of conflict and refrain from any undue participation in the particular matter involved. 3 Minutes from Previous Committee Meeting • Instead of having the Secretary read the minutes, copies have been distributed for your review. • They are located just after the conflict of interest statement in the P&T Booklet that was emailed out. • Are there any additions or corrections to the minutes? • If not, the minutes will stand approved as is.
    [Show full text]